Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX, Liu FR, Zhang Y, Chen Q, Chen ZQ, Liu QW, Huang Y, Yang YP, Fang WF, Xi N, Kang N, Zhuang YL, Zhang Q, Jiang YZ, Zhang L, Zhao HY.
Ma YX, et al. Among authors: zhang l, zhang q, zhang y.
Front Immunol. 2022 Oct 20;13:1024755. doi: 10.3389/fimmu.2022.1024755. eCollection 2022.
Front Immunol. 2022.
PMID: 36341335
Free PMC article.
Clinical Trial.